Adagene Inc., of Suzhou, China, closed a $28 million series B financing led by GP Healthcare Capital, with participation from new investor New World TMT and current investors Eight Roads Ventures China (formerly Fidelity Growth Partners Asia), F-Prime Capital (formerly Fidelity Biosciences) and Wuxi Corporate Venture Fund.